ENGN Stock Forecast & Price Target

enGene Therapeutics is facing some near-term setbacks in the clinical development of their flagship product detalimogene, leading to a decline in efficacy metrics. However, their proprietary DDX platform and potential for improved urothelial transfection with the addition of polidocanol could improve the product's performance. The company also has a strong cash position and relatively low adverse event rates, but concerns about their CMO's exit and regulatory uncertainties could impact their potential in the competitive NMIBC market. Despite these challenges, there is still a compelling opportunity for safer and easier-to-use therapies in the community setting for NMIBC, but the company's overall outlook is currently uncertain.

enGene Therapeutics is facing significant challenges as their lead candidate, Detalimogene, shows a lackluster response in their ongoing LEGEND trial for NMIBC. With increased operating expenses and a lack of clarity on the data, questions remain about the drug's efficacy and its potential in the market. Key data metrics, such as their 12-month durability rate and 6-month complete response rate, may not be competitive enough for FDA approval. This, coupled with uncertainty surrounding the CMO role, lowers confidence in the company's short-term outlook and warrants a downgrade to NEUTRAL.